BioCentury
ARTICLE | Clinical News

Cyramza ramucirumab: Phase II data

June 22, 2015 7:00 AM UTC

Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Cyramza ramucirumab ( LY3009806, IMC-1121B) Business: Cancer Molecular target: Vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-...